Abbvie (ABBV) PT Raised to $126 at Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Abbvie (ABBV) PT Raised to $135 at RBC Capital
February 4, 2021 7:00 AM ESTRBC Capital analyst Randall Stanicky raised the price target on Abbvie (NYSE: ABBV) to $135.00 (from $129.00) while maintaining a Outperform rating. Overall, the outlook feels stable and very notably to Stanicky like a clear contrast to large cap biopharma peers dealing with mid-2020's... More
